Site icon Nairametrics

Nigerian biotech startup becomes first African lab to offer liquid biopsy to advance cancer diagnosis

African lab, Syndicate Bio, SOPHiA GENETICS,

Nigeria-based biotechnology startup, Syndicate Bio. has partnered with SophiaGenetics, a cloud-native software firm specializing in data-driven medicine, to become the inaugural laboratory in Africa to offer comprehensive genomic profiling and liquid biopsy services on a continent-wide scale.

The partnership marks a significant milestone in Africa’s healthcare landscape, promising unprecedented access to cutting-edge genomic technologies previously unavailable to patients across the continent.

By leveraging Sophia Genetics’ expertise in cloud-based healthcare solutions, Syndicate Bio aims to democratize genetic testing and empower healthcare providers with advanced diagnostic capabilities.

Partnership’s significance on Africa’s cancer care

Dr. Abasi Ene-Obong, Founder of Syndicate Bio and former co-founder and CEO of 54gene, emphasized the potential of the collaboration, stating, “Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, thereby enhancing patient outcomes continent-wide.”

What you should know

According to the Chief Medical Officer of SOPHiA Genetics’, who highlighted the laboratory’s role in shaping global healthcare through the creation of comprehensive datasets, the significance of this partnership extends beyond immediate clinical impact.

By leveraging data insights, the collaboration aims to drive innovation, accelerate drug discovery, and ultimately improve health outcomes worldwide.

News continues after this ad

 

Exit mobile version